Tepmetko® Too Expensive For Lung Cancer Treatment? Global Access Guide For Affordable Tepotinib Alternative

Summary - This blog explains how patients with metastatic non-small cell lung cancer can access an affordable equivalent of Tepotinib (Tepmetko®) globally through compliant personal importation. It covers how the medicine works, why Tepmetko® remains very expensive & how patients may obtain a high-quality, affordable alternative through MedsPartner.

Non-small cell lung cancer (NSCLC) accounts for roughly 85% of all lung cancer diagnoses globally. And around 85,000 people worldwide each year have a MET exon 14 skipping alteration that drives their cancer. For these patients, tepotinib (Tepmetko®) is a targeted oral treatment with demonstrated benefits. 

Despite this, thousands of patients cannot afford this life-saving medicine. In the US, branded Tepmetko® costs approximately USD 12,907 for a 30-tablet supply - and since no generic equivalent is yet available, patients face mounting medicine bills, often even with insurance. The situation is similar in many countries across the globe.

Through MedsPartner, we solve this treatment hurdle by helping patients source an affordable tepotinib equivalent from an EU GMP-approved manufacturer in Germany. Here is how patients everywhere can make use of this option.

How does Tepotinib (Tepmetko®) work?

Tepotinib is an oral targeted therapy used for adults with metastatic NSCLC whose tumours have MET exon 14 skipping alterations. 

In some people with NSCLC, a change called a MET exon 14 skipping alteration causes the MET protein to stay switched on, sending constant signals that tell cancer cells to grow and survive. Tepotinib is a targeted therapy designed to block the MET protein and shut down these abnormal signals. By cutting off the growth signals the cancer depends on, it can help slow or stop tumour growth. Because tepotinib specifically targets cancers with this MET alteration, its effects are focused on tumour cells carrying this genetic change. 

One important property of tepotinib is that it can cross the blood-brain barrier, which is useful for patients who develop brain metastases.

Why is Tepmetko® so expensive in the USA & other countries?

Tepmetko® was developed specifically for those with METex14 skipping NSCLC - which represents a relatively small group within the broader lung cancer market. Targeted therapies developed for small subgroups are typically priced higher to reflect their clinical value & the research investment required to identify, validate, and bring them to market.

In the US, Tepmetko® is available only as a branded medicine with no domestic generic. This means patients without commercial insurance or with high specialty tier coinsurance face the full retail price. Even insured patients may be subject to specialty tier copays of 20-30%, leaving monthly out-of-pocket costs in the thousands before deductibles are met. Patients across the globe face similar challenges. In these scenarios, an affordable tepotinib alternative provided by MedsPartner via compliant personal importation can be a feasible solution.

What is the price of Tepmetko® compared to the MedsPartner tepotinib alternative?

Standard dose of Tepmetko®  is 450mg once daily - two 225mg tablets per day, totalling 60 tablets per month. In the US, branded Tepmetko® is the only available option, as no equivalent has been approved for domestic sale yet.

MedsPartner's tepotinib alternative is sourced from an EU GMP-approved manufacturer in Germany - following the same regulatory standard that applies to medicines sold across the European Union. It offers an affordable alternative to those who cannot manage the US prices. Pricing is available on enquiry; contact the MedsPartner team or visit the product page for current details.

Is global personal import of Tepotinib variants legal?

Yes. A number of countries allow patients to import prescription medicines for their own personal use, in limited quantities, provided they hold a valid prescription & follow all destination-country regulations. MedsPartner ships tepotinib in accordance with each patient's local import guidelines, easing the complexity of cross-border import by managing everything for the customer.

Patients across 45+ countries, including UK, Australia, New Zealand, and many others, have used MedsPartner's personal import pathway to access medicines that would otherwise be unaffordable or unavailable locally. Reach out to our team on support@medspartner.com to learn more about how this works for your country.

How can I place an order for Tepotinib on MedsPartner?

Start by reviewing product details on the MedsPartner tepotinib product page & submit an enquiry or order request. Once your prescription is received, the team reviews it, checks the personal import requirements for your country, and lets you know if any additional documents are needed. We then share the payment details and next steps.

After your confirmation and payment, your medicine is sourced from the EU GMP-approved manufacturer in Germany & dispatched with the necessary customs documentation. The aim is to keep the process manageable so patients & their families can stay focused on treatment.

Why should I trust the Tepotinib equivalent from MedsPartner?

The tepotinib alternative supplied by MedsPartner is manufactured in Germany by an EU GMP-approved facility - meaning it meets the same manufacturing quality standards required for medicines sold anywhere in the European Union. 

All medicines undergo quality & authenticity checks before dispatch, and patients receive manufacturer details & expiry information with each order, with real-time shipment tracking available until delivery.

MedsPartner has been operating for over 9 years, with over 30,000 successful international deliveries of affordable meds & holds a 4.8-star rating on Trustpilot from patients across the world.

Case Study - Accessing Tepotinib for a Patient in the Philippines

Mona, a 61-year-old in Manila, was diagnosed with metastatic NSCLC & genetic testing identified a MET exon 14 skipping alteration. Tepotinib was the recommended targeted treatment. Tepmetko® is not covered under PhilHealth or the Philippine government's benefit packages for cancer treatment, leaving patients to pay private pharmacy prices that Mona’s family could not sustain for an ongoing daily medication.

A local patient support group suggested exploring personal import options, and Mona discovered MedsPartner after looking for options online. After providing a valid prescription & supporting medical documents, Mona was able to access a tepotinib equivalent through MedsPartner, manufactured in Germany to EU GMP standards & shipped to Manila. Mona was able to continue her treatment at a fraction of the cost, without the fear of facing steep medicine bills every month.

FAQs on Tepmetko® & affordable Tepotinib alternatives

Q1. Is the tepotinib equivalent from MedsPartner as effective as branded Tepmetko®?

A - The tepotinib equivalent offered by MedsPartner contains the same active ingredient as branded Tepmetko® & is manufactured in Germany by an EU GMP-approved facility, meeting the same quality standards required for medicines across the European Union. This ensures similar efficacy at a lower price point.

Q2. How much can I save by accessing tepotinib through MedsPartner?

A - Branded Tepmetko® costs approximately USD 25,814 per month for standard dosing in the US, with no domestic equivalent currently available. MedsPartner's tepotinib alternative is available at a significantly lower cost - contact the team or visit the product page for current pricing information.

Q3. Is it legal to import a tepotinib equivalent for personal use?

A - In most countries, yes - personal import of prescription medicines is permitted in limited quantities for patients with a valid prescription & a few other supporting documents as per that specific country’s rules. MedsPartner's team can explain how this works in your specific country & process your order in line with local personal import laws.

Q4. How can I trust the quality of the tepotinib alternative from MedsPartner?

A - The tepotinib supplied by MedsPartner is manufactured in Germany under EU GMP certification - the same quality standard that applies to all medicines manufactured for sale within the EU. Every shipment includes manufacturer details & expiry information, and can be tracked in real time. Patient reviews are available on Trustpilot, where MedsPartner holds a 4.8-star rating.

Q5. I am an oncologist. How can I arrange affordable tepotinib for my patients?

A - Email support@medspartner.com with your patient's details & prescription. The MedsPartner team will reach out to your patient directly, verify all documents & arrange shipment from the vetted manufacturer in Germany in line with the patient's local import regulations.

Q6. Is Tepmetko® (tepotinib) chemotherapy or immunotherapy?

A - No, Tepmetko (tepotinib) is neither chemotherapy nor immunotherapy. It is a targeted therapy designed for people with non-small cell lung cancer (NSCLC) with a MET exon 14 skipping alteration. Unlike chemotherapy - which attacks rapidly dividing cells throughout the body, or immunotherapy - which helps the immune system fight cancer, Tepmetko works by blocking the abnormal MET protein that drives the growth of these cancer cells. This targeted approach allows it to specifically treat tumours with the MET alteration.

Q7. What are the common side effects of Tepmetko® / tepotinib?

A - Common side effects of Tepmetko®  include edema, nausea, diarrhoea, fatigue, and musculoskeletal pain. Liver enzyme elevations are also possible and are monitored through blood tests. If you notice significant swelling, shortness of breath, or signs of liver problems such as jaundice, contact your doctor promptly. Your doctor can recommend dose adjustments or other steps for side effect management.

Q8. What is the step-by-step process for ordering through MedsPartner?

A - Visit the tepotinib product page & submit an enquiry or order request - no payment is required at this point. Upload your valid prescription, and the MedsPartner team will verify it, check your country's import requirements & confirm what documentation is needed. Once we receive everything from you & the payment is made, we will source your medicine from the EU GMP facility in Germany & ship it with all required customs paperwork.

Q9. What if my insurance denies coverage or demands a high co-pay for Tepmetko®?

A - Ask your oncologist to submit a prior authorisation appeal supported by your METex14 test results, treatment history & clinical justification for tepotinib. EMD Serono's CoverOne programme offers copay assistance of up to USD 15,000 per year for eligible commercially insured US patients, & a bridge programme provides an initial free prescription for patients experiencing insurance delays. If coverage still cannot be arranged at an affordable cost, MedsPartner offers a quality-assured lower-cost alternative that allows treatment to continue.

Q10. Are there other support options for accessing Tepmetko® affordably?

A - The Patient Access Network (PAN) Foundation provides financial assistance for eligible patients in the US, and EMD Serono's own CoverOne patient assistance programme covers some commercially insured patients. But eligibility depends on income, insurance status & eligibility criteria. For patients who do not qualify or who need access more quickly than program timelines allow, MedsPartner's import pathway offers a dependable alternative.

Making Tepotinib treatment more affordable for everyone

Tepmetko® is a high-cost, targeted oncology medicine with no domestic equivalent available in the US and many other countries yet. MedsPartner's tepotinib alternative - manufactured in Germany to EU GMP standards - gives NSCLC patients a way to access their prescribed treatment without the full burden of branded pricing.

Need guidance on personal importation of affordable Tepotinib? Write to us to learn how to access an affordable tepotinib alternative safely & legally in your country, or visit the tepotinib product page to get started.

About the Author - Ramesh Baranwal has over a decade of experience in pharmaceutical procurement, logistics & international operations. At MedsPartner - he manages sourcing, warehousing & global supply coordination - to ensure that every medicine reaches patients safely and compliantly. His expertise in import-export management helps streamline complex cross-border deliveries - making affordable & authentic treatments accessible worldwide.